Biotechnology company Cellesce has been acquired by a global life science provider for an undisclosed sum. The Cardiff-headquartered firm has been bought by multi-national US firm, Molecular Devices LLC.
Cellesce specialises in contract development and manufacturing of large-scale patient-derived organoids (PDOs) for diverse applications, including large scale drug screening. The acquisition will strengthen Molecular Devices' human-relevant 3D biology research and accelerate adoption of relevant cell models for drug discovery.
Cellesce produces uniform, human-derived cell or organoid lines including off-the-shelf colorectal cancer, gastrointestinal, and breast cancer organoids — with pancreatic and lung organoids under development — all at a scale unmatched by any commercial technology available today. The company’s quality-assured, patented bioprocess workflow and unique bioreactors have been proven to increase productivity 20- to 60-fold.
